Trial · NCT03829319
Adverse events2,580
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 2,580
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Part 1 First Course: Pembrolizumab+Chemotherapy+Lenvatinib | 1 | 13 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib | 192 | 373 | 394 |
| other | Anaemia | Blood and lymphatic system disorders | Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo | 220 | 372 | 419 |
| other | Anaemia | Blood and lymphatic system disorders | Part 1 Second Course: Pembrolizumab Only From Pembrolizumab+Chemotherapy+Lenvatinib | 0 | 1 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Part 2 Second Course: Pembrolizumab+Chemotherapy+Lenvatinib | 1 | 3 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Part 2 Second Course: Pembrolizumab+Chemotherapy+Placebo | 0 | 7 | 0 |
| other | Atrial fibrillation | Cardiac disorders | Part 1 First Course: Pembrolizumab+Chemotherapy+Lenvatinib | 1 | 13 | 1 |
| other | Atrial fibrillation | Cardiac disorders | Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib | 4 | 373 | 9 |
| other | Atrial fibrillation | Cardiac disorders | Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo | 1 | 372 | 1 |
| other | Atrial fibrillation | Cardiac disorders | Part 1 Second Course: Pembrolizumab Only From Pembrolizumab+Chemotherapy+Lenvatinib | 0 | 1 | 0 |
| other | Atrial fibrillation | Cardiac disorders | Part 2 Second Course: Pembrolizumab+Chemotherapy+Lenvatinib | 0 | 3 | 0 |
| other | Atrial fibrillation | Cardiac disorders | Part 2 Second Course: Pembrolizumab+Chemotherapy+Placebo | 0 | 7 | 0 |
| other | Adrenal insufficiency | Endocrine disorders | Part 1 First Course: Pembrolizumab+Chemotherapy+Lenvatinib | 1 | 13 | 1 |
| other | Adrenal insufficiency | Endocrine disorders | Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib | 10 | 373 | 10 |
| other | Adrenal insufficiency | Endocrine disorders | Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo | 3 | 372 | 3 |
| other | Adrenal insufficiency | Endocrine disorders | Part 1 Second Course: Pembrolizumab Only From Pembrolizumab+Chemotherapy+Lenvatinib | 0 | 1 | 0 |
| other | Adrenal insufficiency | Endocrine disorders | Part 2 Second Course: Pembrolizumab+Chemotherapy+Lenvatinib | 0 | 3 | 0 |
| other | Adrenal insufficiency | Endocrine disorders | Part 2 Second Course: Pembrolizumab+Chemotherapy+Placebo | 0 | 7 | 0 |
| other | Hyperthyroidism | Endocrine disorders | Part 1 First Course: Pembrolizumab+Chemotherapy+Lenvatinib | 1 | 13 | 1 |
| other | Hyperthyroidism | Endocrine disorders | Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib | 26 | 373 | 30 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03829319/events